SEATTLE, WA--(Marketwire - March 06, 2013) - Atossa Genetics, Inc.
), The Breast Health Company™, announced today that Steven C. Quay, M.D., Ph.D., FCAP, chairman, CEO & president, and Kyle Guse, CFO and general counsel, will present the Company's business model, growth strategy and products and services at the 25th Annual ROTH Conference at the Ritz-Carlton Laguna Niguel in Dana Point, California, on Tuesday, March 19, 2013, at 3:30 pm Pacific Time.
Dr. Quay commented, "This is Atossa's first time presenting at this much anticipated event. We appreciate the opportunity afforded to us to discuss our growth strategy and provide an update on the national rollout of our ForeCYTE Breast Health Test, which is a highly significant development that positions Atossa for accelerated growth in 2013 and beyond. In addition, the rollout of the ArgusCYTE Breast Health Test and launch of the FullCYTE and NextCYTE breast health tests, as well as securing a partner for clinical development of our intraductal therapy this year, each represent significant upside potential in 2013."
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, regulatory actions, Atossa's responses to regulatory actions, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's, filings including its registration statement form S-1 filed January 28, 2013, as amended and supplemented from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.